Generic Medicine Info
Indications and Dosage
Malignant neoplasms
Adult: 1-3 g/m2 daily for 5 days.

Malignant neoplasms
Adult: Up to 1 g/m2 daily. Usually used with uracil.

Advanced colorectal cancer
Adult: 300 mg/m2 tegafur combined with 672 mg/m2 uracil daily in 3 divided doses, together with calcium folinate. Doses are given for a cycle of 28 days, followed by 7 days without treatment.
Pregnancy, lactation. Hypersensitivity.
Special Precautions
Weak or malnourished patients, hepatic and renal impairment, history of cardiac disease, acute infections. Determine blood count frequently.
Adverse Reactions
Nausea, vomiting, anorexia, mucositis, malaise, hot flushes, oedema, itching, central neurotoxicity, bone-marrow depression, stomatitis, haemorrhage, skin rashes, alopoecia, ocular irritation, myocardial ischaemia,
Drug Interactions
Concurrent use increased risk of neurotoxicity with leflunomide; increased risk of phenytoin toxicity with phenytoin; increased anticoagulation effect of warfarin; increased risk of myelosupression with colony stimulating factors eg. filgrastim; increased risk of thrombosis with tamoxifen; increased risk of toxicity with folic acid.
Potentially Fatal: Increased risk of severe toxicity with sorivudine.
Description: Tegafur is an antineoplastic agent that acts as an antimetabolite. It is a prodrug of fluorouracil that is administered orally.
Absorption: Well absorbed in GI tract.
Distribution: Crosses the blood-brain barrier and is found in the CSF.
Metabolism: Metabolised slowly in the liver to fluorouracil; some intracellular conversion to fluorouracil may also occur. Plasma half-life of 6-16 hr (IV).
MIMS Class
Cytotoxic Chemotherapy
Disclaimer: This information is independently developed by MIMS based on Tegafur from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in